Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05882877 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
A Phase 3 study of Atopic Dermatitis, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 2,621
- Enrollment target
- 20
- Study locations
NCT05882877: Active Phase 3 study of Atopic Dermatitis, sponsored by Amgen.
NCT05882877 is a Phase 3 study of Atopic Dermatitis that is active but no longer recruiting, run by Amgen. The registered enrollment target is 2,621 participants, above the 592-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (343% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05882877, a Phase 3 study of Atopic Dermatitis, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,621 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Rocatinlimab
Study Locations (20)
California
- Kern Research Inc - Bakersfield
- Hope Clinical Research LLC - Canoga Park
- West Coast Research LLC - Dublin
- California Dermatology and Clinical Research Institute - Encinitas
- First OC Dermatology - Fountain Valley
- Antelope Valley Clinical Trials - Lancaster
- Chemidox Clinical Trials Incorporated - Lancaster
- Long Beach Research Institute - Long Beach
- University of California Los Angeles - Los Angeles
- Dermatology Research Associates - Los Angeles
- Wallace Medical Group Inc - Los Angeles
- Northridge Clinical Trials - Northridge
Arizona
- Medical Dermatology Specialists - Phoenix
- Alliance Dermatology and Mohs Center - Phoenix
- Affiliated Dermatology - Scottsdale
- Scottsdale Clinical Trials - Scottsdale
Arkansas
- Dermatology Trial Associates - Bryant
- Burke Pharmaceutical Research - Hot Springs
- Arkansas Research Trials, LLC - North Little Rock
Alabama
- Cahaba Dermatology and Skin Health Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,621 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 3 |
What the registry record for NCT05882877 still lists
NCT05882877 is an interventional study that assigns participants to a tested intervention. Its 2,621 participants enrollment target places it among the larger protocols in the corpus, above the 592-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (343% higher).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05882877 names 20 study sites across 4 states, led by California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05882877 about?
NCT05882877 is a clinical study titled "A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)". The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
What is the current status of trial NCT05882877?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 2,621 participants. The study started on 2023-05-31. Estimated completion is 2027-06-30.
What conditions does trial NCT05882877 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT05882877?
The interventions under investigation include: Placebo (OTHER), Rocatinlimab (DRUG).
Who is sponsoring clinical trial NCT05882877?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05882877 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05882877's enrollment target sits among peer trials
2,621 6th of 150 higher than 145 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06455085 · 2,634 participants · NA
RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE
- NCT06033950 · 2,600 participants · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
- NCT06574672 · 2,600 participants · NA
Embedded Palliative Care in the MICU
- NCT06370520 · 2,592 participants
Screening Emotions in Adolescents at the Hospital for mTBI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI